Top Ozempic Brands Revolutionizing Diabetes Care

Ozempic has rapidly gained popularity as a leading medication for managing type 2 diabetes, offering effective blood sugar control and weight management. As the demand for Ozempic increases, so too does the interest in identifying the best pharmaceutical brands that produce and distribute it. Several companies have established themselves as reliable producers, known for maintaining high standards of manufacturing and innovation in diabetes care. To learn more about these reputable brands and their unique offerings, explore the list below.

Illustration of ozempic

Best brands of ozempic in 2025

Novo Nordisk

Novo Nordisk is a leading global healthcare company renowned for its innovative diabetes treatments, including Ozempic (semaglutide), which has been a game-changer in the management of type 2 diabetes. Since its approval by the FDA in 2017, Ozempic has demonstrated significant efficacy, with clinical trials showing up to a 20% reduction in major adverse cardiovascular events. The medication has also been associated with substantial weight loss, making it a preferred choice for many patients. As of 2023, Ozempic has been prescribed to millions of patients worldwide, highlighting its widespread acceptance and effectiveness. Novo Nordisk's commitment to research and development has positioned Ozempic as a flagship product in the diabetes care market.

Pfizer

Novo Nordisk, not Pfizer, is the innovative force behind Ozempic, a highly successful medication. This drug has seen remarkable sales growth, totaling $13.9 billion in 2023, which marks a 38% rise from the previous year. Ozempic is primarily prescribed for type 2 diabetes but is also renowned for its anti-obesity effects, boosting its popularity. In 2022, it generated $8.5 billion in sales, with 65% originating from the U.S. market. Novo Nordisk's total sales soared to $28.4 billion in 2023, with Ozempic alone constituting 40% of that impressive figure, underscoring its significant impact on the company's financial success.

Eli Lilly

Eli Lilly is making significant strides in the GLP-1 market with its innovative products, Mounjaro and Zepbound. Unlike being the producer of Ozempic, Eli Lilly is capturing attention with Mounjaro, approved in 2022, which saw a remarkable 71% quarterly growth and a 215.5% year-over-year sales increase in Q2 2024. Zepbound is also making an impressive mark with a 140% quarterly growth. These medications are exceeding some metrics over Novo Nordisk's Ozempic, with Mounjaro demonstrating superior weight loss outcomes in comparative trials. By Q2 2024, Mounjaro achieved $3.09 billion in sales, while Zepbound secured approximately 40% of the U.S. weight-loss drug market. GlobalData anticipates Mounjaro sales to reach an astounding $34 billion by 2029.

Sanofi

Sanofi, although not the primary producer of Ozempic, is a significant player in the GLP-1 analogue market with its own products like Soliqua. Soliqua, a combination of insulin glargine and lixisenatide, received approval in China in January 2023 for treating adults with type 2 diabetes mellitus and gained National Reimbursement Drug List (NRDL) status in December 2023, enhancing its market reach and patient accessibility. Sanofi's strong geographical presence and wide customer base across over 80 countries contribute to its market standing. However, Ozempic, produced by Novo Nordisk, remains the dominant GLP-1 product, with a 34.17% market share in 2024 and a 70% growth rate between 2019 and 2023. For further insights on the GLP-1 market dynamics, you can request a sample report from MarketsandMarkets.

GlaxoSmithKline

In the landscape of pharmaceuticals, Novo Nordisk emerges as the manufacturer of Ozempic (semaglutide), not GlaxoSmithKline. The drug has witnessed remarkable sales growth, achieving $13.9 billion in 2023, representing a 38% increase from the previous year. Ozempic stands as a pivotal force in the GLP-1 market, fortifying Novo Nordisk's robust market presence and establishing the company as Europe's most valuable public entity with a market capitalization nearing $490 billion. Noteworthy are the promising results of Ozempic in reducing cardiovascular risks, with studies demonstrating a 20% reduction in incidents like heart attacks, strokes, and cardiovascular fatalities. Furthermore, it is projected that Ozempic, alongside other anti-obesity medications, will propel the AOM industry's value to $100 billion by 2030. By 2035, these drugs are anticipated to be utilized by 7% of the U.S. population. For more detailed insights, you can explore the comprehensive report from Novo Nordisk.

AstraZeneca

AstraZeneca, although not the producer of Ozempic, has made significant strides in the GLP-1 receptor agonist market through its licensing agreement with Eccogene for the oral GLP-1RA, ECC5004. This agreement, announced in November 2023, includes an initial upfront payment of $185 million and up to $1.825 billion in future milestones and royalties. ECC5004 is poised to offer an alternative to injectable GLP-1RAs, such as Ozempic, which dominated the market with a 34.17% share in 2024. AstraZeneca's move is part of its strategy to expand its cardiometabolic and obesity pipeline, targeting the estimated one billion people living with these conditions. The company's global capabilities in clinical development and commercialization are expected to accelerate the development of ECC5004. For more detailed information, visit the AstraZeneca's official announcement.

Merck & Co.

Merck & Co. is not the producer of Ozempic; instead, Novo Nordisk is the company behind this highly successful GLP-1 therapy. Ozempic (semaglutide) saw a significant sales increase of 38% in 2023, reaching $13.9 billion in sales, making it one of the top-selling drugs globally. This growth underscores the rising importance of metabolic disease treatments, with Ozempic playing a pivotal role. Novo Nordisk's sales jumped by more than one-third in 2023, driven largely by Ozempic's success. The drug's impact is further highlighted by its expanded label for cardiovascular risk reduction in March 2024. For more details on the best-selling pharmaceuticals of 2023, visit Drug Discovery Trends.

Novartis

Novartis is not the producer of Ozempic; instead, Novo Nordisk A/S is the major company operating in the Ozempic market. Ozempic, a weekly injection for diabetes and weight management, is expected to reach a market size of USD 10.99 billion in 2024 and grow at a CAGR of greater than 8% to reach USD 16.5 billion by 2029. Novo Nordisk's Ozempic drove significant growth, with the drug accounting for 43% of the company's overall sales. The North American region holds the largest market share and is also the fastest-growing region for Ozempic. Novo Nordisk's semaglutide formulations, including Ozempic, have seen substantial year-over-year increases, such as a 30% increase for Ozempic itself. For more detailed insights, you can view the Ozempic market report.

Roche

Roche is not a producer of Ozempic; rather, it is directing its efforts towards its own obesity and diabetes treatments. Roche has acquired Carmot Therapeutics to develop innovative drugs such as CT-388, a dual GLP-1 and GIP receptor modulator, and CT-996, a GLP-1 receptor agonist, which have demonstrated promising weight loss results alongside severe gastrointestinal side effects. These medications are expected to launch commercially in 2028 or beyond, with projected annual sales reaching up to $3.6 billion. Conversely, Ozempic is a product of Novo Nordisk, leading the GLP-1 receptor agonist market with a 34.17% share in 2024 and generating substantial revenue. Novo Nordisk's Ozempic has been approved for treating type 2 diabetes and has shown significant benefits in reducing cardiovascular risk and weight.

Johnson & Johnson

Johnson & Johnson is not the producer of Ozempic; instead, Novo Nordisk is the company behind this highly successful diabetes and weight loss medication. Ozempic generated $3.2 billion in revenue for Novo Nordisk in the second quarter of 2023, up from $2.1 billion the previous year, and it accounts for 43% of Novo Nordisk's overall sales. Johnson & Johnson, however, is a leading pharmaceutical company with significant market share, ranking first in total sales with $4.73 billion and a market share of 12.2%.